Stock of the Day

December 25, 2023

argenx (ARGX)

$644.48
-$3.01 (-0.5%)
Market Cap: $39.34B

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

argenx Bull Case

Here are some ways that investors could benefit from investing in argenx SE:

  • Recent upgrades from multiple analysts, including a target price increase to $725.00, indicate strong market confidence in argenx SE's growth potential.
  • The stock has a consensus rating of "Moderate Buy," suggesting that the majority of analysts believe the stock is a good investment opportunity.
  • Current stock price is $639.41, which is significantly higher than its 12-month low of $349.86, showing a strong recovery and potential for further growth.
  • Argentx SE is actively developing therapies for autoimmune diseases, a growing market with increasing demand for innovative treatments.
  • The company has a solid market capitalization of $38.85 billion, indicating a strong position in the biotechnology sector.

argenx Bear Case

Investors should be bearish about investing in argenx SE for these reasons:

  • Despite positive ratings, one analyst has issued a sell rating, which could indicate potential risks or concerns about the company's future performance.
  • The stock has a high price-to-earnings ratio of -726.60, suggesting that the company is not currently profitable, which may deter risk-averse investors.
  • Recent downgrades from some analysts, such as Baird R W moving from "strong-buy" to "hold," may signal caution regarding the stock's short-term performance.
  • Market volatility can impact stock prices significantly, and biotechnology stocks are often subject to rapid changes based on clinical trial results and regulatory approvals.
  • With a beta of 0.58, the stock is less volatile than the market, which may limit potential high returns for aggressive investors looking for rapid growth.

Recent News